Literature DB >> 23231878

Cognitive behaviour therapy for psychosis can be adapted for minority ethnic groups: a randomised controlled trial.

Shanaya Rathod1, Peter Phiri, Scott Harris, Charlotte Underwood, Mahesh Thagadur, Uma Padmanabi, David Kingdon.   

Abstract

UNLABELLED: Cognitive behavioural therapy (CBT) is recommended in treatment guidelines for psychotic symptoms (NICE, 2009) but clients from some minority groups have been shown to have higher dropout rates and poorer outcomes. A recent qualitative study in ethnic minority groups concluded that CBT would be acceptable and may be more effective if it was culturally adapted to meet their needs (Rathod et al., 2010). AIM: This study assessed the effectiveness of a culturally adapted CBT for psychosis (CaCBTp) in Black British, African Caribbean/Black African and South Asian Muslim participants.
METHOD: A randomised controlled trial was conducted in two centres in the UK (n=35) in participants with a diagnosis of a disorder from the schizophrenia group. Assessments were conducted at three time points: baseline, post-therapy and at 6 months follow-up, using the Comprehensive Psychopathological Rating Scale (CPRS) and Insight Scale. Outcomes on specific subscales of CPRS were also evaluated. Participants in the treatment arm completed the Patient Experience Questionnaire (PEQ) to measure satisfaction with therapy. Assessors blind to randomisation and treatment allocation conducted administration of outcome measures. In total, n=33 participants were randomly allocated to CaCBTp arm (n=16) and treatment as usual (TAU) arm (n=17) after (n=2) participants were excluded. CaCBTp participants were offered 16 sessions of CaCBTp with trained therapists and the TAU arm continued with their standard treatment.
RESULTS: Analysis was based on the principles of intention to treat (ITT). This was further supplemented with secondary sensitivity analyses. Post-treatment, the intervention group showed statistically significant reductions in symptomatology on overall CPRS scores, CaCBTp Mean (SD)=16.23 (10.77), TAU=18.60 (14.84); p=0.047,with a difference in change of 11.31 (95% CI:0. 14 to 22.49); Schizophrenia change: CaCBTp=3.46 (3.37); TAU=4.78 (5.33) diff 4.62 (95% CI: 0.68 to 9.17); p=0.047 and positive symptoms (delusions; p=0.035, and hallucinations; p=0.056). At 6 months follow-up, MADRAS change=5.6 (95% CI: 2.92 to 7.60); p<0.001. Adjustment was made for age, gender and antipsychotic medication. Overall satisfaction was significantly correlated with the number of sessions attended (r=0.563; p=0.003).
CONCLUSION: Participants in the CaCBTp group achieved statistically significant results post-treatment compared to those in the TAU group with some gains maintained at follow-up. High levels of satisfaction with the CaCBTp were reported.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23231878     DOI: 10.1016/j.schres.2012.11.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

1.  Enhancing the Engagement of Immigrant and Ethnocultural Minority Clients in Canadian Early Intervention Services for Psychosis.

Authors:  Anika Maraj; Srividya N Iyer; Jai L Shah
Journal:  Can J Psychiatry       Date:  2018-08-01       Impact factor: 4.356

2.  The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments.

Authors:  Michael E Thase; David Kingdon; Douglas Turkington
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

3.  Providers' perspectives of factors influencing implementation of evidence-based treatments in a community mental health setting: A qualitative investigation of the training-practice gap.

Authors:  Luana Marques; Louise Dixon; Sarah E Valentine; Christina P C Borba; Naomi M Simon; Shannon Wiltsey Stirman
Journal:  Psychol Serv       Date:  2016-06-09

4.  Receipt and targeting of evidence-based psychosocial interventions for people living with psychoses: findings from the second Australian national survey of psychosis.

Authors:  C Harvey; J Lewis; J Farhall
Journal:  Epidemiol Psychiatr Sci       Date:  2018-06-12       Impact factor: 6.892

5.  Does Cognitive Behavior Therapy for psychosis (CBTp) show a sustainable effect on delusions? A meta-analysis.

Authors:  Stephanie Mehl; Dirk Werner; Tania M Lincoln
Journal:  Front Psychol       Date:  2015-10-06

Review 6.  The evolution of cognitive-behavioral therapy for psychosis.

Authors:  Helen Mander; David Kingdon
Journal:  Psychol Res Behav Manag       Date:  2015-02-18

7.  A qualitative study to explore views of patients', carers' and mental health professionals' to inform cultural adaptation of CBT for psychosis (CBTp) in China.

Authors:  Weihui Li; Li Zhang; Xuerong Luo; Bangshan Liu; Zhipeng Liu; Fang Lin; Zhiling Liu; Yuhuan Xie; Melissa Hudson; Shanaya Rathod; David Kingdon; Nusrat Husain; Xudong Liu; Muhammad Ayub; Farooq Naeem
Journal:  BMC Psychiatry       Date:  2017-04-08       Impact factor: 3.630

8.  Pilot randomised controlled trial of culturally adapted cognitive behavior therapy for psychosis (CaCBTp) in Pakistan.

Authors:  Muhammed Omair Husain; Imran B Chaudhry; Nasir Mehmood; Raza Ur Rehman; Ajmal Kazmi; Munir Hamirani; Tayyeba Kiran; Ameer Bukhsh; Paul Bassett; Muhammad Ishrat Husain; Farooq Naeem; Nusrat Husain
Journal:  BMC Health Serv Res       Date:  2017-12-06       Impact factor: 2.655

Review 9.  Interventions to improve therapeutic communications between Black and minority ethnic patients and professionals in psychiatric services: systematic review.

Authors:  Kamaldeep S Bhui; Rabeea'h W Aslam; Andrea Palinski; Rose McCabe; Mark R D Johnson; Scott Weich; Swaran P Singh; Martin Knapp; Vittoria Ardino; Ala Szczepura
Journal:  Br J Psychiatry       Date:  2015-08       Impact factor: 9.319

10.  Ethnic variations in compulsory detention and hospital admission for psychosis across four UK Early Intervention Services.

Authors:  Farhana Mann; Helen L Fisher; Barnaby Major; Jo Lawrence; Andrew Tapfumaneyi; John Joyce; Mark F Hinton; Sonia Johnson
Journal:  BMC Psychiatry       Date:  2014-09-05       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.